致病性BRCA突变状态的瘤结果在年轻的光线性乳腺癌中:一种倾向匹配的队列
Woong Ki Park1, Seok Jin Nam1, Seok Won Kim1
1Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
JCO precision oncology
|January 14, 2026
概括
在ER阳性,HER2阴性乳腺癌的年轻女性中,BRCA突变与更具侵略性的疾病和更差的远程无转移存活率有关. 这凸显了针对BRCA载体量身定制的监测和治疗策略的必要性.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 患有雌激素受体 (ER) 阳性,人体表皮生长因子受体2 (HER2) 阴性乳腺癌的年轻患者 (≤40岁) 通常面临着不良预后.
- 在这个特定的患者群体的结果中,BRCA突变的作用仍然是积极研究的领域.
研究的目的:
- 为了评估BRCA突变在被诊断为ER阳性,HER2阴性乳腺癌的年轻女性的预后影响.
- 为了比较BRCA突变携带者和非携带者之间的瘤结果,特别是远程转移无生存率 (DMFS) 和整体生存率.
主要方法:
- 一个潜在的机构队列的回顾性分析,包括967名ER阳性,HER2阴性乳腺癌的年轻患者,他们接受了BRCA1/2测试.
- 使用倾向分数匹配 (1:4) 和多变量考克斯回归来调整潜在的混因素.
- 低ER表达的患者被排除在分析之外.
主要成果:
- 携带BRCA突变的携带者 (10.1%) 呈现出更具侵略性的瘤特征.
- 与非携带者相比,携带者对DMFS (HR,1.76;P = .038) 的情况明显较差,特别是超过5年的晚期DMFS (HR,2.84;P = .009),与非携带者相比.
- 骨是载体中最常见的第一个转移部位,而非载体中更常见的是多个转移部位. 总体存活率没有显著差异.
结论:
- 具有光型年轻乳腺癌 (YBC) 的BRCA携带者表现出更具侵略性的特征和更糟糕的远程转移结果.
- 这些发现强调了长期监测BRCA载体的重要性.
- 考虑向治疗,如PARP抑制剂,对于这种高风险人群是有必要的.
更多相关视频
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
13.8K
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
12.6K
相关概念视频
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
